Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men
- PMID: 7903313
- DOI: 10.1210/jcem.77.6.7903313
Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men
Abstract
Bolus injection of the synthetic hexapeptide GH-releasing peptide-6 (GHRP-6) reliably promotes GH secretion. However, desensitization to the GH-releasing effects of GHRP has been shown to occur during short term iv infusion. To determine whether humans would remain responsive to prolonged exposure to GHRP and to study the mechanism of action of GHRP, we compared the effects of a 34-h iv infusion of either GHRP or normal saline on parameters of pulsatile GH concentration in nine healthy young men. Each infusion was administered from 0800 h on day 1 to 1800 h on day 2. GHRP was given as a 1 microgram/kg loading bolus, then at the rate of 1 microgram/kg.h. A 50-microgram iv bolus of TRH was given at 0800 h on day 2, followed by iv boluses of GH-releasing hormone (GHRH; 1 microgram/kg, iv, at 1000, 1200, and 1400 h) and then a bolus of GHRP (1 microgram/kg at 1600 h). The integrated GH concentration (IGHC) and parameters of pulsatile GH concentration were calculated for the period between 1400 h on day 1 to 0800 h on day 2, and IGHC was calculated for 2 h after each bolus of GHRP or GHRH. During GHRP infusion, there was a significant increase in IGHC (2908 +/- 450 vs. 1374 +/- 160 micrograms x min/L), maximum pulse amplitude (15.2 +/- 2.8 vs. 8.4 +/- 1.7 micrograms/L), and mean pulse amplitude (7.0 +/- 1.1 vs. 3.8 +/- 1.5 micrograms/L). Plasma insulin-like growth factor-I increased from 252 +/- 23 to 312 +/- 23 micrograms/L. There was no change in either GH pulse frequency or interpulse GH concentration. During GHRP infusion, the GH responses to the GHRH boluses were augmented; however, baseline TSH was lower, and the GH and TSH/PRL responses to GHRP and TRH, respectively, were smaller. We conclude that the pituitary remains sensitive to GHRP during a prolonged GHRP infusion. The mechanisms of the GHRP effect on GH secretion are uncertain, and the possibility that GHRP acts as a functional somatostatin antagonist is discussed. The contrasting effects of GHRP on GH and TSH/PRL secretion could be due to differential effects of GHRP on the pituitary and hypothalamus.
Similar articles
-
Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.J Clin Endocrinol Metab. 1993 May;76(5):1202-8. doi: 10.1210/jcem.76.5.8496311. J Clin Endocrinol Metab. 1993. PMID: 8496311
-
Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.J Clin Endocrinol Metab. 1990 Jul;71(1):157-63. doi: 10.1210/jcem-71-1-157. J Clin Endocrinol Metab. 1990. PMID: 1973420
-
Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.J Clin Endocrinol Metab. 1999 Jun;84(6):2140-50. doi: 10.1210/jcem.84.6.5687. J Clin Endocrinol Metab. 1999. PMID: 10372723 Clinical Trial.
-
Growth hormone-releasing peptides: clinical and basic aspects.Horm Res. 1996;46(4-5):155-9. doi: 10.1159/000185015. Horm Res. 1996. PMID: 8950613 Review.
-
Physiological role of somatostatin on growth hormone regulation in humans.Metabolism. 1990 Sep;39(9 Suppl 2):40-2. doi: 10.1016/0026-0495(90)90207-s. Metabolism. 1990. PMID: 1976218 Review.
Cited by
-
Somatostatin and somatostatin receptor physiology.Endocrine. 2003 Apr;20(3):255-64. doi: 10.1385/ENDO:20:3:255. Endocrine. 2003. PMID: 12721505 Review.
-
Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.Endocrine. 2001 Feb;14(1):79-86. doi: 10.1385/ENDO:14:1:079. Endocrine. 2001. PMID: 11322505 Clinical Trial.
-
Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro.J Endocrinol Invest. 2003 Aug;26(8):743-7. doi: 10.1007/BF03347357. J Endocrinol Invest. 2003. PMID: 14669829
-
The effects of a continuous infusion of hexarelin on pulsatile growth hormone release, growth axis and galanin gene expression and on the response of the growth axis to growth hormone-releasing hormone.Pituitary. 2000 May;2(4):253-60. doi: 10.1023/a:1009957015563. Pituitary. 2000. PMID: 11081146
-
Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.Endocrine. 2001 Feb;14(1):45-62. doi: 10.1385/ENDO:14:1:045. Endocrine. 2001. PMID: 11322501 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources